Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | CMA1 | P23946 | 15/20 | 0.44 |
| ▸ | CTRC | Q99895 | 13/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765810 | 0.87 | CTRC (0.47) | NTRK1CMA1CTRCNTRK3 | |
| SCHEMBL30765887 | 0.86 | NTRK1 (0.41) | NTRK1GAAL3MBTL1NTRK3 | |
| SCHEMBL30765506 | 0.79 | NTRK1 (0.51) | NTRK1CMA1CTRCNTRK3 | |
| SCHEMBL30765824 | 0.74 | NR1H2 (0.44) | NTRK1CMA1CTRCNTRK3 | |
| SCHEMBL30765484 | 0.74 | CMA1 (0.53) | NTRK1CMA1CTRCNTRK3 | |
| Hydrochloric Acid SCHEMBL30765589 | 0.73 | CMA1 (0.53) | NTRK1CMA1CTRCNTRK3 | |
| SCHEMBL30765639 | 0.72 | L3MBTL1 (0.41) | NTRK1L3MBTL1 | |
| SCHEMBL30765718 | 0.71 | NTRK1 (0.45) | NTRK1CMA1CTRCNTRK3 | |
| SCHEMBL30765911 | 0.70 | ELANE (0.40) | NTRK1GAAL3MBTL1NTRK3 | |
| SCHEMBL30765599 | 0.66 | CTRC (0.54) | CMA1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |